Taken together, these data provide the first evidence that α1AT administration may be a valid approach for the treatment of PT-mediated pertussis manifestations in infants and support the need for further studies to comprehensively evaluate and optimize α1AT treatment strategies for this severe disease. Here, SERPINA1 is linked to pertussis.